EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 350 filers reported holding EXELIXIS INC in Q4 2020. The put-call ratio across all filers is 2.32 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $20,000 | -20.0% | 1,100 | 0.0% | 0.01% | -21.4% |
| Q1 2021 | $25,000 | +13.6% | 1,100 | 0.0% | 0.01% | +7.7% |
| Q4 2020 | $22,000 | -18.5% | 1,100 | 0.0% | 0.01% | -23.5% |
| Q3 2020 | $27,000 | +3.8% | 1,100 | 0.0% | 0.02% | 0.0% |
| Q2 2020 | $26,000 | +85.7% | 1,100 | +37.5% | 0.02% | +54.5% |
| Q1 2020 | $14,000 | 0.0% | 800 | 0.0% | 0.01% | +22.2% |
| Q4 2019 | $14,000 | +27.3% | 800 | +33.3% | 0.01% | +28.6% |
| Q3 2019 | $11,000 | -42.1% | 600 | -33.3% | 0.01% | -46.2% |
| Q2 2019 | $19,000 | -9.5% | 900 | 0.0% | 0.01% | -13.3% |
| Q1 2019 | $21,000 | -8.7% | 900 | -30.8% | 0.02% | -6.2% |
| Q3 2018 | $23,000 | -17.9% | 1,300 | 0.0% | 0.02% | -23.8% |
| Q2 2018 | $28,000 | -3.4% | 1,300 | 0.0% | 0.02% | +5.0% |
| Q1 2018 | $29,000 | -75.2% | 1,300 | -66.2% | 0.02% | -73.7% |
| Q4 2017 | $117,000 | -2.5% | 3,850 | -22.2% | 0.08% | -6.2% |
| Q3 2017 | $120,000 | – | 4,950 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 15,001,073 | $265,294,000 | 64.62% |
| Sargent Investment Group, LLC | 465,620 | $8,234,000 | 3.70% |
| Orbimed Advisors | 3,912,900 | $69,200,000 | 1.31% |
| Bellevue Group AG | 3,858,700 | $68,241,000 | 1.27% |
| TEALWOOD ASSET MANAGEMENT INC | 137,129 | $2,425,000 | 1.04% |
| CAPITAL MANAGEMENT CORP /VA | 200,995 | $3,555,000 | 0.97% |
| Penn Capital Management Company, LLC | 517,988 | $9,161,000 | 0.96% |
| Chicago Capital, LLC | 801,560 | $14,176,000 | 0.95% |
| Portolan Capital Management | 454,444 | $8,037,000 | 0.91% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,534 | $1,830,000 | 0.85% |